diffusion through synthetic membranes, ensuring batch-to-batch consistency and formulation performance.

2. Scope

This SOP applies to all AMD laboratory personnel involved in the development, validation, and execution of IVRT methods for semi-solid topical formulations intended for dermal application.

3. Responsibilities

• Analytical Scientist: Designs and executes IVRT studies and ensures membrane integrity and method suitability.
• Formulation Scientist: Provides formulation composition, expected release profiles, and performance criteria.
• QA Officer: Reviews validation data, checks protocol adherence, and ensures GMP compliance.
• Head – AMD: Approves the IVRT protocol and validation report for use in regulatory submissions.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that IVRT methods are robust, validated, and reproducible for accurate characterization of topical drug products.

5. Procedure

5.1 Selection of IVRT Equipment and Membrane

1. Use vertical diffusion cells (e.g., Franz diffusion cells) with appropriate donor and receptor chambers.
2. Select synthetic membranes such as:
   • Cellulose acetate
   • Silicone
   • Hydrophilic polysulfone (e.g., Strat-M)
3. Hydrate membrane before use and test for integrity (leak test).

5.2 Receptor Medium Selection

1. Choose receptor medium that ensures drug solubility (sink conditions):
2. Common media:
   • Phosphate buffer (pH 6.8–7.4)
   • Ethanol-water (40:60)
   • SLS-containing buffer (if required for solubilization)

5.3 Sample Application and Diffusion Setup

1. Maintain receptor compartment at 32 ± 1°C using a water bath circulator.
2. Load 300–500 mg of formulation evenly on the membrane surface in the donor chamber.
3. Clamp the cell assembly tightly and initiate magnetic stirring in the receptor chamber.

5.4 Sampling and Analysis

1. Withdraw samples (e.g., 0.5–1.0 mL) from the receptor medium at intervals: 0.5, 1, 2, 3, 4, 6, 8 hours.
2. Immediately replace withdrawn volume with pre-warmed fresh receptor medium.
3. Analyze collected samples using validated HPLC or UV methods.
4. Calculate cumulative amount of drug released (µg/cm²) and record in Annexure-1: IVRT Data Sheet.

5.5 Plotting and Modeling

1. Prepare drug release profiles (% cumulative release vs. time).
2. Use model fitting to evaluate kinetics:
   • Zero-order
   • First-order
   • Higuchi model
   • Korsmeyer-Peppas model
3. Record modeling results in Annexure-2: Release Kinetics Summary.

5.6 Method Validation

1. Perform IVRT validation in accordance with ICH Q2(R2), covering:
   • Precision (inter- and intra-day)
   • Linearity of cumulative release
   • Reproducibility across cells
   • System suitability criteria (e.g., %RSD ≤ 10%)
2. Summarize in Annexure-3: IVRT Method Validation Report.

5.7 Acceptance Criteria

1. Compare release rates between formulations (e.g., RLD vs Test).
2. IVRT pass criteria may include:
   • f₂ similarity ≥ 50
   • Mean release rate within ±15% of reference

6. Abbreviations

• IVRT: In-Vitro Release Testing
• RLD: Reference Listed Drug
• f₂: Similarity Factor
• SLS: Sodium Lauryl Sulfate
• SOP: Standard Operating Procedure

7. Documents

1. IVRT Data Sheet – Annexure-1
2. Release Kinetics Summary – Annexure-2
3. IVRT Method Validation Report – Annexure-3

8. References

• FDA Guidance for Topical Generic Drug Products
• ICH Q2(R2) – Validation of Analytical Procedures
• USP <1724> – Semisolid Drug Products—Performance Tests
• EMA Reflection Paper on IVRT and IVPT

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: IVRT Data Sheet

Time (hr)	Amount Released (µg/cm²)	Analyst
0.5	12.8	Sunita Reddy
1	21.5	Sunita Reddy
2	33.1	Sunita Reddy

Annexure-2: Release Kinetics Summary

Model	R² Value	Interpretation
Higuchi	0.994	Diffusion-controlled release
Zero-order	0.913	Not suitable

Annexure-3: IVRT Method Validation Report

Parameter	Result	Acceptance Criteria	Status
Inter-day Precision	%RSD = 6.2%	≤ 10%	Pass
Linearity	R² = 0.9985	≥ 0.995	Pass

Revision History:

Revision Date	Revision No.	Details	Reason	Approved By
04/05/2025	2.0	Added kinetic modeling and validation parameters	Annual SOP Review